A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

Completed · Phase 2 · Has a placebo group

Conditions studied: Active Non-segmental Vitiligo

In brief

This is a Phase 2b, randomized, double blind, parallel group, multicenter study with an extension period. The study will have a maximum duration of approximately 60 weeks. This includes an up to 4 weeks Screening Period, a 24 week dose ranging period, an up to 24 week extension period and a 8 week Follow up Period.

Key facts

Study ID

NCT03715829

Run by

Pfizer

People needed

366

Starts

2018-11-26

Expected to finish

2021-02-05

Last updated by the study team

2022-03-25

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female subjects between 18-65 years of age, inclusive, at time of informed consent.
• Must have moderate to severe active non-segmental vitiligo.

You may not qualify if…

• History of human immunodeficiency virus (HIV) or positive HIV serology at screening,
• Infected with hepatitis B or hepatitis C viruses.
• Have evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB)

Where it is running

• University of California, Irvine, Dermatology Clinical Research Center — Irvine, California, United States
• Vitiligo and Pigmentation Institute Of Southern California — Los Angeles, California, United States
• Dermatology Specialist, Inc. — Murrieta, California, United States
• Dermatology Specialists, Inc. — Oceanside, California, United States
• UC Davis Health — Sacramento, California, United States
• Brookside Dermatology Associates — Bridgeport, Connecticut, United States
• New England Research Associates, LLC — Bridgeport, Connecticut, United States
• New Horizon Research Center — Miami, Florida, United States
• Park Avenue Dermatology — Orange Park, Florida, United States
• ForCare Clinical Research — Tampa, Florida, United States
• Advanced Skin and MOHS Surgery Center, c/o TrialSpark, Inc. — Chicago, Illinois, United States
• Chevy Chase Dermatology Center (TrialSpark, Inc.) — Chevy Chase, Maryland, United States
• TrialSpark - Samantha Toerge, MD — Chevy Chase, Maryland, United States
• TrialSpark - Ronald Shore, MD — Rockville, Maryland, United States
• Tobias & Battite, Inc. — Boston, Massachusetts, United States
• Tufts Medical Center — Boston, Massachusetts, United States
• UMass Memorial Medical Center, Hahnemann Campus — Worcester, Massachusetts, United States
• Investigational Drug Service Pharmacy — Worcester, Massachusetts, United States
• UMass Memorial Medical Center Ear Nose and Throat — Worcester, Massachusetts, United States
• University of Massachusetts Medical School — Worcester, Massachusetts, United States
• Henry Ford Hospital Department of Dermatology — Detroit, Michigan, United States
• University of Minnesota Department of Dermatology — Minneapolis, Minnesota, United States
• The Dermatology Group, P.C. — Verona, New Jersey, United States
• Icahn School of Medicine at Mount Sinai — New York, New York, United States
• Marvel Research, LLC — Huntington Beach, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.